Finding new treatments for severe anticoagulant poisoning
Development of novel anticoagulant antidotes using zebrafish
This project looks for new medicines to quickly reverse the dangerous bleeding caused by strong rat poisons, which can accidentally or intentionally harm people.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11134609 on NIH RePORTER |
What this research studies
Superwarfarins are powerful poisons, often found in rodenticides, that can cause severe and prolonged bleeding in people. Current treatments, like high doses of vitamin K, can take a long time to work and may require weeks or months of expensive care. This research aims to discover faster-acting antidotes that could be given orally and would be easier to store and distribute than current emergency treatments. By using innovative technologies with zebrafish, scientists hope to identify new compounds that can quickly stop the bleeding and save lives.
Who could benefit from this research
Good fit: Future patients who experience severe bleeding due to accidental or intentional poisoning with superwarfarins could potentially benefit from these new antidotes.
Not a fit: Patients with bleeding conditions not caused by superwarfarin poisoning would not directly benefit from these specific antidotes.
Why it matters
Potential benefit: If successful, this work could lead to new, more effective, and faster-acting antidotes for severe superwarfarin poisoning, potentially saving lives and reducing long hospital stays.
How similar studies have performed: While vitamin K is a known antidote, this project uses highly innovative technologies to discover novel, faster-acting antidotes, representing a new approach to this problem.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Shavit, Jordan a. — University of Michigan at Ann Arbor
- Study coordinator: Shavit, Jordan a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.